Bexarotene plus Erlotinib Suppresses Lung Carcinogenesis Independent of KRAS Mutations in Two Clinical Trials and Transgenic Models

The rexinoid bexarotene represses cyclin D1 by causing its proteasomal degradation. The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib represses cyclin D1 via different mechanisms. We conducted a preclinical study and two clinical/translational trials (a window-of-...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Dragnev, Konstantin H., Ma, Tian, Cyrus, Jobin, Galimberti, Fabrizio, Memoli, Vincent, Busch, Alexander M., Tsongalis, Gregory J., Seltzer, Marc, Johnstone, David, Erkmen, Cherie P., Nugent, William, Rigas, James R., Liu, Xi, Freemantle, Sarah, Kurie, Jonathan M., Waxman, Samuel, Dmitrovsky, Ethan
Formato: Artigo
Idioma:Inglês
Publicado: 2011
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3108499/
https://ncbi.nlm.nih.gov/pubmed/21636548
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1940-6207.CAPR-10-0376
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares